Circio Holding ASA – Exercise of subscription rights in the rights issue by primary insiders

Summary by AI ^BETAClose X

Circio Holding ASA announced that Biopharma Drug Licensing Group, SL, a company closely associated with CFO Lubor Gaal, has subscribed for 270,000 offer shares in the ongoing rights issue at NOK 1.00 per share. This subscription includes the exercise of 65,164 subscription rights and an additional 204,836 shares subscribed for without rights, with a corresponding allocation of warrants expected.

Disclaimer*

Oslo, 29 January 2026: Reference is made to the stock exchange announcements by Circio Holding ASA (the “Company“) on 15 January 2026, regarding the commencement of the subscription period for the rights issue (the “Rights Issue“) and the receipt of subscription rights in the Rights Issue by certain primary insiders and close associates.

Certain primary insiders and close associates have on the dates as stated below, exercised subscription rights and subscribed for shares:

Biopharma Drug Licensing Group, SL, a closely associated company of Lubor Gaal, CFO of the Company, has on 28 January 2026 exercised 65,164 subscription rights, thus entitling the company to be allocated 65,164 offer shares in the Rights Issue. In addition, Biopharma Drug Licensing Group has subscribed for 204,836 offer shares without subscription rights, thereby subscribing for a total of 270,000 offer shares at the subscription price in the Rights Issue, i.e., NOK 1.00 per offer share, and to be allocated a corresponding number in warrants without additional consideration, subject to allocation by the board of directors and the completion of the Rights Issue.

Please see the attached notifications of trade for information regarding the subscription rights exercised by primary insiders in the Rights Issue.

This information is subject to the disclosure requirements pursuant to article 19 of the EU Market Abuse Regulation and section 5-12 of the Norwegian Securities Trading Act.